Onxeo
PARIS, FR· latest recorded location
ONXEO is named on 10 US grants and 16 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 10
- Published applications
- 16
- Inventors
- 25
- Granted in 2026 so far
- 0
- Most recent grant
- 8 Mar 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 2 | 0 |
| 2016 | 0 | 0 |
| 2017 | 2 | 3 |
| 2018 | 0 | 2 |
| 2019 | 1 | 2 |
| 2020 | 3 | 4 |
| 2021 | 1 | 1 |
| 2022 | 1 | 2 |
| 2023 | 0 | 1 |
By publication year.
Technology areas
Share of 26 documents
Recent patents
- Oral formulations of belinostat8 Mar 2022US 11,266,614 B2
- Use of a combination of Dbait molecule and PARP inhibitors to treat cancer2 Nov 2021US 11,162,095 B2
- Treatment of cancer by systemic administration of Dbait molecules3 Nov 2020US 10,821,128 B2
- Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates8 Sep 2020US 10,765,758 B2
- Use of a combination of Dbait molecule and PARP inhibitors to treat cancer18 Feb 2020US 10,563,197 B2
- A dbait molecule in combination with kras inhibitor for the treatment of cancer27 Jul 2023US 2023/0235327 A1
- A dbait molecule in combination with kinase inhibitor for the treatment of cancer12 May 2022US 2022/0143049 A1
- New conjugated nucleic acid molecules and their uses24 Feb 2022US 2022/0054524 A1
- Treatment of cancer by systemic administration of dbait molecules28 Jan 2021US 2021/0023116 A1
- A dbait molecule against acquired resistance in the treatment of cancer31 Dec 2020US 2020/0407720 A1
Most cited
By later US patents
- Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates4US 9,687,557 B22017
- Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates2US 10,363,317 B22019
- Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates1US 10,765,758 B22020
- Nanoparticles loaded with chemotherapeutic antitumoral drug1US 9,763,874 B22017